Seeking Alpha

Shares of St. Jude Medical (STJ +3%) claw back a bit of their 12% pummeling taken on Wednesday...

Shares of St. Jude Medical (STJ +3%) claw back a bit of their 12% pummeling taken on Wednesday following the FDA's release of a report citing serious flaws in STJ's oversight of Durata. BofA Merrill Lynch notes that the report found no new safety issues and the probability of a recall stands well below 50%, which is already priced into the stock. It reiterates a Buy with a potential downside to $24 and an upside peaking around $40.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs